Our data have also confirmed Cyclin E1 overexpression as a predictor of sensitivity to azenosertib monotherapy in PROC, and we intend to pursue further development in this patient population.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback